News

Genetic testing holds great promise, but there are some critical drawbacks to consider.

Republicans recently unveiled their ACA replacement plan. Here’s what the experts say you need to know.

Technology experts predict that more health plans will take advantage of consumer engagement technologies in 2017.

A new drug to treat moderate-to-severe plaque psoriasis carries a black box warning that suicidal ideas and behavior, including completed suicides, have occurred in patients during the drug’s clinical trials.

A leading asthma inhaler will now be available to additional younger asthma patients, after FDA approved Spiriva Respimat (Boehringer Ingelheim) for the long-term, once-daily maintenance treatment of asthma in people age 6 and older.

Investment in resources that support clinicians and patients closer to the point of care may be the cure for what ails managed care executives.

Health insurance has served different purposes over the years. It may be time to rethink today’s system.

Will Trump’s policies hamper or improve healthcare access? Experts weigh in.

A Precision for Value survey highlights what can be done in order to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment.

Allegheny Health Network (AHN) in Pittsburgh, Pennsylvania, has achieved what few health systems have been able to do-offer same-day specialty appointments across its hospital network.

We asked healthcare industry leaders, what apps should managed care executives check out? Here's what they said.

Marathon Pharmaceuticals is temporarily pausing the launch of its drug to treat a rare form of muscular dystrophy (MD) after concerns over its $89,000 price tag.

Here’s how experts say the blocked Aetna-Humana and Anthem-Cigna mergers will affect consolidation among payers and providers.

FDA recently approved 2 new therapies: an expanded drug indication for locally advanced or metastatic urothelial carcinoma (mUC) and a treatment for secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.

Report highlights spending trends in key areas, including specialty medications, oncology, diabetes, and inflammatory conditions.

Here’s what a Vizient’s hospital leader survey says about the future of the Affordable Care Act (ACA) and other healthcare policies under the new Administration.

Scott Winiecki, MD, of the FDA Center for Drug Evaluation and Research, shares how the FDA is working to address the opioid epidemic.

SCOTUS nominee Judge Neil Gorsuch could have an impact on healthcare. Here’s how.

How can physicians, already struggling to keep up with mounting regulations and larger patient loads, use PDMPs in more effective and efficient ways?

Commonwealth Fund’s 2016 Biennial Health Insurance Survey found significant improvements in people’s ability to buy health plans on their own after implementation of the ACA insurance reforms.

A new report highlights the top states most affected by repeal of the ACA. Is your state among the top 10?

FDA is warning about rare but serious allergic reactions have from the widely-used skin antiseptic products containing chlorhexidine gluconate.

In the latest flap over the high cost of drugs, diabetes patients filed a class-action lawsuit against insulin makers.

Several changes and transitions will have a huge impact on health IT in 2017 and in future years.

At Cigna, technology is viewed as a strategic enabler that powers its business strategy-creating closer, more meaningful connections with customers.

Experts share updates on new diabetes medications, and provide an overview of what’s coming.

In order to survive as a managed care organization, it’s important to stay on top of policy changes and reimbursement trends.

Managed Healthcare Executive’s 2017 Technology Survey findings reveal that tools to help consumers estimate the cost of healthcare may be underutilized. Here’s what UnitedHealthcare is doing about that.

Patients need cost information to make the best treatment decisions. But physicians are coming up short.

Three candidates that President Donald Trump is considering for FDA Commissioner are likely to speed drug approvals, analysts say.